Targeting JAK-STAT signal transduction in IBD

Christoffer Soendergaard; Fredrik Holmberg Bergenheim; Jakob Tveiten Bjerrum; Ole Haagen Nielsen

doi:10.1016/j.pharmthera.2018.07.003

Targeting JAK-STAT signal transduction in IBD

Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen

Institut for Klinisk Medicin

37 Citationer (Scopus)

Abstract

An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

Originalsprog	Engelsk
Tidsskrift	Pharmacology & Therapeutics
Vol/bind	192
Sider (fra-til)	100-111
ISSN	0163-7258
DOI	https://doi.org/10.1016/j.pharmthera.2018.07.003
Status	Udgivet - dec. 2018

Adgang til dokumentet

10.1016/j.pharmthera.2018.07.003

Citationsformater

@article{a93a4ab66d1b4a099755af50aa85a3bd,

title = "Targeting JAK-STAT signal transduction in IBD",

abstract = "An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.",

author = "Christoffer Soendergaard and Bergenheim, {Fredrik Holmberg} and Bjerrum, {Jakob Tveiten} and Nielsen, {Ole Haagen}",

year = "2018",

month = dec,

doi = "10.1016/j.pharmthera.2018.07.003",

language = "English",

volume = "192",

pages = "100--111",

journal = "Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and",

issn = "0163-7258",

publisher = "Elsevier",

}

TY - JOUR

T1 - Targeting JAK-STAT signal transduction in IBD

AU - Soendergaard, Christoffer

AU - Bergenheim, Fredrik Holmberg

AU - Bjerrum, Jakob Tveiten

AU - Nielsen, Ole Haagen

PY - 2018/12

Y1 - 2018/12

N2 - An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

AB - An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

U2 - 10.1016/j.pharmthera.2018.07.003

DO - 10.1016/j.pharmthera.2018.07.003

M3 - Journal article

C2 - 30048708

SN - 0163-7258

VL - 192

SP - 100

EP - 111

JO - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and

JF - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and

ER -

Targeting JAK-STAT signal transduction in IBD

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater